Optimisation de la dose de tacrolimus avec surveillance thérapeutique et polymorphisme du CYP3A5 chez les MG

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

Optimisation de la dose de tacrolimus avec surveillance thérapeutique et polymorphisme du CYP3A5 chez les MG

Message par Pboulanger Prés. »

:hi:

:arrow: Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/29611886

[ligne][/ligne]

Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en

Image

[ligne][/ligne]

Dose optimisation of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in myasthenia gravis patients.
Chen D1, Hou S2, Zhao M1, Sun X1, Zhang H2, Yang L1.
Eur J Neurol. 2018 Apr 3. doi: 10.1111/ene.13652.


Abstract

  • BACKGROUND AND PURPOSE:

    Tacrolimus was beneficial for treatment of myasthenia gravis (MG). And it has a narrow therapeutic range, therefore, therapeutic drug monitoring (TDM) is essential for tacrolimus to optimize dosage and prevent adverse reactions. However, no studies have explored the influencing factors of tacrolimus blood concentration in MG patients. Thus, we aimed to analyze the influencing factors and discuss how to optimal tacrolimus dosage for MG treatment.
  • METHODS:

    The data of clinical characteristics, therapeutic drugs and adverse reactions of patients with MG who received tacrolimus were collected from 2013 to 2015 in Beijing Hospital. Tacrolimus whole-blood concentrations were measured by chemiluminescent microparticle immunoassay (CMIA) and CYP3A5*3 gene polymorphism was detected by digital fluorescence molecule hybridization fluorescence. Regression analysis was applied to analyze the influencing factors of blood concentrations and adverse reactions.
  • RESULTS:

    It was shown that there was a certain correlation between concentration and dosage. Furthermore, co-administration of proton pump inhibitor (PPI) and clarithromycin and CYP3A5*3 gene polymorphism could significantly increase the tacrolimus whole blood levels. The adverse reaction was related
  • to blood concentration, CYP3A5 genetic polymorphisms and combined medication though logistic regression analysis.
    CONCLUSIONS:

The concentration of tacrolimus is affected by many factors. TDM and detection of CYP3A5 polymorphism gene was essential for dosage optimization in MG patients.

Message d' un membre de l'équipe technique
Pour les utilisateurs d'I-phone
ci-dessous le lien vers Google Trad

https://translate.google.fr/translate?h ... 2F29611886
Message d' un membre de l'équipe technique
Nous utilisons des services automatiques de traduction fournis
par Yandex ou Google.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.
Amicalement,
Image
Verrouillé

Retourner vers « 2018 »